Ghotaslou A, Nadali F, Chahardouli B, Alizad Ghandforosh N, Rostami S H, Alimoghaddam K, Ghavamzadeh A
MS.c Student , Department of Hematology,School of Allied Medical Sciences , Tehran university of Medical Sciences, Tehran , Iran.
Associate Professor, Departement of Hematology, School of Allied Medical Sciences , Tehran university of Medical Sciences , Tehran, Iran.
Iran J Ped Hematol Oncol. 2015;5(1):43-9. Epub 2015 Mar 15.
Myeloproliferative disorders are a group of diseases characterized by increased proliferation of myeloid lineage. In addition to JAK2V617F mutation, several mutations in the c-MPL gene have been reported in patients with philadelphia-negative chronic myeloproliferative disorders that could be important in the pathogenesis of diseases. The aim of the present study was to investigate the frequency of c-MPL and JAK2V617F mutations in Iranian patients with Philadelphia-negativemyeloproliferative disorders.
Peripheral blood samples were collected from 60 patients with Philadelphia-negative MPD) Subgroups ET and PMF) and 25 healthy subjects as control group. The mutation status of c-MPL and Jak2V617F were investigated by using Amplification-refractory mutation system (ARMS) and Allele-Specific PCR (AS-PCR), respectively. The results were confirmed by sequencing.
Among 60 patients, 34 (56.6%) and 1(1.7%) had Jak2V617F and c-MPL mutation, respectively. Patients with Jak2V617F mutation had higher WBC counts and hemoglobin concentration than those without the mutation (p= 0.005, p=0.003). In addition, for all healthy subjects in control group, mutations were negative.
The present study revealed that the c-MPL mutations unlike the Jak2V617F mutations are rare in Iranian patients with Ph-negative MPNs and the low mutation rate should be considered in the design of screening strategies of MPD patients.
骨髓增殖性疾病是一组以髓系细胞增殖增加为特征的疾病。除JAK2V617F突变外,在费城阴性慢性骨髓增殖性疾病患者中还报道了c-MPL基因的几种突变,这些突变可能在疾病的发病机制中起重要作用。本研究的目的是调查伊朗费城阴性骨髓增殖性疾病患者中c-MPL和JAK2V617F突变的频率。
采集60例费城阴性骨髓增殖性疾病(ET和PMF亚组)患者的外周血样本,并采集25名健康受试者作为对照组。分别采用扩增阻滞突变系统(ARMS)和等位基因特异性PCR(AS-PCR)检测c-MPL和Jak2V617F的突变状态。结果通过测序进行确认。
60例患者中,分别有34例(56.6%)和1例(1.7%)发生Jak2V617F和c-MPL突变。Jak2V617F突变患者的白细胞计数和血红蛋白浓度高于未发生突变的患者(p = 0.005,p = 0.003)。此外,对照组所有健康受试者的突变均为阴性。
本研究表明,与Jak2V617F突变不同,c-MPL突变在伊朗费城阴性骨髓增殖性肿瘤患者中罕见,在设计骨髓增殖性疾病患者的筛查策略时应考虑到这种低突变率。